A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is a post-marketing surveillance study conducted as part of the Risk Management Plan (RMP) for South Korea, to evaluate the safety and effectiveness of iptacopan in real-world clinical settings for the treatment of either PNH or C3G in Korean patients. Prospective data will be collected from patient medical records to address the objectives for all eligible populations.
Epistemonikos ID: f6dbc799d2fcfbdd3b9fb06e2e902ca9c3b7d9a3
First added on: Feb 19, 2026